Brief: Quantum Genomics Launches Phase III Pivotal REFRESH Study In Difficult-To-Treat/Resistant Hypertension With Once-A-Day Formulation Of Firibastat

Quantum Genomics SA

18/01/2021 07:08

Jan 18 (Reuters) - Quantum Genomics SA  ALQGC.PA :
    * QUANTUM GENOMICS LAUNCHES PHASE III PIVOTAL REFRESH STUDY
IN
DIFFICULT-TO-TREAT/RESISTANT HYPERTENSION WITH ONCE-A-DAY
FORMULATION OF FIRIBASTAT
    * SITES SELECTION WILL START SHORTLY, AND REGULATORY
SUBMISSIONS
TO COMPETENT AUTHORITIES AND ETHICS COMMITTEES ARE IN
PREPARATION FOR EACH COUNTRY
    * FIRST PATIENT RECRUITMENT IS PLANNED IN Q2 2021 AND
EFFICACY
RESULTS AND SIX-MONTH SAFETY RESULTS ARE EXPECTED FOR MID-2023
    * STUDY COSTS ARE BUDGETED AND FINANCED THANKS TO THE
PARTNERSHIPS
SIGNED BY QUANTUM GENOMICS
    * NEW STUDY IS PART OF FIRIBASTAT’S PHASE III CLINICAL
DEVELOPMENT
AND AIMS TO ASSESS LONG-TERM SAFETY AS WELL AS THE THREE-MONTH
EFFICACY AFTER A SINGLE DAILY DOSE OF FIRIBASTAT 1000MG IN
TREATMENT RESISTANT HYPERTENSIVE PATIENTS

Source text for Eikon:  ID:nACT67068 
Further company coverage:  ALQGC.PA 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 778 51 10;))